Product Description
The ADC ADRX-0405 is composed of a humanized IgG1 antibody and novel topoisomerase inhibitor linker-payload conjugated at a drug-to-antibody ratio of eight (DAR 8) to maximize payload delivery to solid tumors. (Sourced from: https://www.biospace.com/press-releases/adcentrx-therapeutics-to-showcase-novel-steap1-and-napi2b-adcs-with-oral-and-poster-presentations-at-aacr-2025#:~:text=About%20ADRX%2D0405&text=The%20ADC%20is%20composed%20of,payload%20delivery%20to%20solid%20tumors)
Mechanisms of Action: STEAP1 Inhibitor
Novel Mechanism: Yes
Modality: Antibody Drug Conjugate
Route of Administration: N/A
FDA Designation: Orphan Drug - Gastrointestinal Cancer *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Adcentrx
Company Location: Western America
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Gastrointestinal Cancer|Non-Small-Cell Lung Cancer|Prostate Cancer|Small Cell Lung Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06710379 |
ADRX-0405-001 | P1 |
Recruiting |
Small Cell Lung Cancer|Prostate Cancer|Non-Small-Cell Lung Cancer|Gastrointestinal Cancer |
2026-07-01 |
50% |
2024-11-30 |
Primary Endpoints |